Table.
Baseline characteristics
| Total (n=4147) | Male (n=3079) | Female (n=1068) | P-value | |
|---|---|---|---|---|
| Age: years, mean ± SD | 65.8±11.8 | 64.5±11.5 | 69.5±11.8 | <0.0001 |
| Sex (female): no. (%) | 1068 (25.8) | - | - | - |
| BMI: kg/m2, mean ± SD | 29.0±5.7 | 28.9±5.2 | 29.2±7.0 | 0.17 |
| Hypertension: no. (%) | 2502 (60.3) | 1763 (57.3) | 739 (69.2) | <0.0001 |
| Dyslipidemia: no. (%) | 2381 (57.4) | 1759 (57.1) | 622 (58.2) | 0.53 |
| Diabetes: no. (%) | ||||
| Type 1 | 26 (0.6) | 16 (0.5) | 10 (0.9) | 0.14 |
| Type 2 | 1065 (25.7) | 756 (24.6) | 309 (28.9) | 0.004 |
| Smoking: no. (%) | 0.0005 | |||
| Never | 2402 (57.9) | 1731 (56.2) | 671 (62.8) | |
| Remote (quit >1 month ago) | 920 (22.2) | 701 (22.8) | 219 (20.5) | |
| Active | 825 (19.9) | 647 (21.0) | 178 (16.7) | |
| Previous history: no. (%) | ||||
| PCI | 745 (18.0) | 601 (20.1) | 144 (13.9) | <0.0001 |
| MI | 635 (15.3) | 500 (16.7) | 135 (13.0) | 0.005 |
| CABG | 210 (5.1) | 166 (5.5) | 44 (4.2) | 0.1 |
| PAD | 193 (4.7) | 134 (4.4) | 59 (5.5) | 0.12 |
| CVA | 178 (4.3) | 122 (4.0) | 56 (5.2) | 0.08 |
| Heart failure | 138 (3.3) | 96 (3.1) | 42 (3.9) | 0.2 |
| Medications, baseline: no. (%) | ||||
| ASA | 3767 (90.8) | 2779 (90.3) | 988 (92.5) | 0.03 |
| P2Y12 | 3776 (91.1) | 2780 (90.3) | 996 (93.3) | 0.003 |
| ACEi/ARB | 1722 (41.5) | 1265 (41.1) | 457 (42.8) | 0.33 |
| Beta blocker | 1889 (45.6) | 1390 (45.1) | 499 (46.7) | 0.37 |
| Calcium channel blocker | 403 (9.7) | 288 (9.4) | 115 (10.8) | 0.18 |
| Statin | 2888 (69.6) | 2136 (69.4) | 752 (70.4) | 0.52 |
| PPI | 492 (11.9) | 319 (10.4) | 173 (16.2) | <0.0001 |
| Investigations, baseline | ||||
| Creatinine: mean +/– SD (mmol/L) | 93.7±68.1 | 96.4±67.1 | 86.2±70.3 | <0.0001 |
| CrCl: mL/min, mean +/– SD | 91.1±40.2 | 96.2±39.5 | 77.0±38.8 | <0.0001 |
| LVEF (n=1138) | 0.06 | |||
| Normal | 813 (71.4) | 564 (69.4) | 249 (76.6) | |
| >45% | 134 (11.8) | 104 (12.8) | 30 (9.2) | |
| 30%-45% | 139 (12.2) | 109 (13.4) | 30 (9.2) | |
| <30% | 52 (4.6) | 36 (4.4) | 16 (4.9) | |
| Mitral valvulopathy (≥moderate) | 53 (1.3) | 30 (1.0) | 23 (2.2) | 0.003 |
| Aortic valvulopathy (≥moderate) | 108 (2.6) | 72 (2.3) | 35 (3.4) | 0.07 |
| Procedural details | ||||
| Indications: no. (%) | ||||
| Acute coronary syndrome | 2670 (64.4) | 1949 (63.3) | 721 (67.5) | 0.01 |
| STEMI | 1160 (28.0) | 863 (44.3) | 297 (41.2) | 0.15 |
| NSTEMI/unstable angina | 1510 (36.4) | 1086 (55.7) | 424 (58.8) | |
| Staged PCI | 311 (7.5) | 242 (7.9) | 69 (6.5) | 0.13 |
| Stable CAD | 1005 (24.2) | 757 (24.6) | 248 (23.2) | 0.37 |
| Shock | 53 (1.3) | 34 (1.1) | 19 (1.8) | 0.09 |
| Access: no. (%) | <0.0001 | |||
| Radial | 3231 (77.9) | 2454 (79.7) | 777 (72.8) | |
| Femoral | 910 (21.9) | 621 (20.2) | 289 (27.1) | |
| Revascularization method: no. (%) | ||||
| PCI | 3535 (85.2) | 2591 (84.2) | 944 (88.4) | 0.001 |
| CABG | 549 (13.2) | 437 (14.2) | 112 (10.5) | 0.002 |
| Both | 63 (1.5) | 51 (1.7) | 12 (1.1) | 0.22 |
| Medications, follow-up: no. (%) | ||||
| ASA | 3393 (81.8) | 2579 (83.8) | 814 (76.2) | <0.0001 |
| P2Y12 | 2360 (56.9) | 1749 (56.8) | 611 (57.2) | 0.82 |
| ACEi/ARB | 2529 (61.0) | 1913 (62.1) | 616 (57.7) | 0.01 |
| Beta blocker | 2678 (64.6) | 1998 (64.9) | 680 (63.7) | 0.47 |
| Calcium channel blocker | 518 (12.5) | 372 (12.1) | 146 (13.7) | 0.18 |
| Statin | 3484 (84.0) | 2619 (85.1) | 865 (81.0) | 0.002 |
| DAPT score ≥2: no. (%) | 1354 (32.7) | 1039 (33.7) | 315 (29.5) | 0.01 |
ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CrCl, creatinine clearance; CVA, cerebrovascular accident; DAPT, dual antiplatelet therapy; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non–ST-elevation MI; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; SD, standard deviation; STEMI, ST-elevation MI.